Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis

Management of non-alcoholic fatty liver disease

(2021) Maria Letizia Petroni et al.   BMJ-British Medical Journal

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

(2021) Haleh Chehrehgosha et al.   Diabetes Therapy

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

(2021) Masato Yoneda et al.   BMJ Open Diabetes Research & Care

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

(2020) Mohammed Eslam et al.   GASTROENTEROLOGY

Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease

(2020) Ling-Yun Zhang et al.   Clinics and Research in Hepatology and Gastroenterology

Nonalcoholic Steatohepatitis

(2020) Adam C. Sheka et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study

(2020) Tomoe Kinoshita et al.   Journal of Diabetes Investigation

Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis

(2020) Simona Panunzi et al.   DIABETES OBESITY & METABOLISM

Treatment options for nonalcoholic fatty liver disease

(2019) Amir Anushiravani et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

(2018) Jan W. Eriksson et al.   DIABETOLOGIA

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

(2018) M Angelyn Bethel et al.   Lancet Diabetes & Endocrinology

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease

(2017) Wenhuan Feng et al.   Journal of Diabetes

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

(2016) Mark M. Smits et al.   DIABETOLOGIA

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies

(2015) Wenjuan Tang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

(2014) Hui Fan et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial

(2013) Mohsen Razavizade et al.   Hepatitis Monthly

GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK

(2013) Lili Zhang et al.   LIVER INTERNATIONAL

Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?

(2012) Marina Shargorodsky et al.   Cardiovascular Diabetology

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

(2012) G. Musso et al.   DIABETOLOGIA

Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non- Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study

(2012) Ali Akbar Hajiaghamohammadi et al.   Hepatitis Monthly

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

(2011) E. Boettcher et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes

(2011) P. K. Shah et al.   DIABETES OBESITY & METABOLISM

The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis

(2011) Suzanne E. Mahady et al.   JOURNAL OF HEPATOLOGY

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metabolic disturbances in non-alcoholic fatty liver disease

(2009) Christopher D. Byrne et al.   CLINICAL SCIENCE

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

(2009) Ziya Omer et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial

(2009) John Willy Haukeland et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

(2008) Guruprasad P. Aithal et al.   GASTROENTEROLOGY